Tokio Marine HCC’s 2026 Annual Market Report underscores two persistent drivers of high-cost claims. In 2025, cancers accounted for 35.2% of total costs and cardiovascular diseases another 12.7% — nearly 48% combined, far more than any other diagnostic categories.
Early detection makes a substantial difference. A recent American Cancer Society analysis found first-year medical costs for colorectal cancer averaged about $49,000 for early-stage disease versus $116,000 for advanced-stage disease. For breast cancer, first-year oral prescription drug costs averaged about $700 for early-stage cancer versus $25,000 for advanced disease.
Cardiovascular disease carries a similar burden. The American Heart Association’s 2026 statistics estimate annual U.S. cardiovascular costs at $414.7 billion, including $223.2 billion in direct medical costs. High blood pressure and high cholesterol remain major modifiable risk factors.
MedBen WellLiving promotes recommended cancer, blood pressure, and cholesterol screenings so these conditions can be addressed earlier — before they become more serious and far more expensive. Contact your broker or MedBen Marketing to learn more.